With Research and development taking centre stage to bring innovation in pharma sector, the focus on the academia-business collaboration has increased significantly in recent years. It has not only helped companies in cutting the cost of R & D but has also ensured sustainable and continuous research to help the sector. The recent R& D centre by Dr Reddy’s in Cambridge is just an addition to that list.
Dr Reddy's Laboratories has opened its newly expanded Chirotech Technology Centre, a purpose-built facility to house its laboratories and offices, at the Cambridge Science Park, UK. The Chirotech R&D facility wasacquired by Dr Reddy's Laboratories from Dow Pharma along with its manufacturing facility in Mirfield, UK, in 2008 at $32 mn.
The new centre, with 33,000 sq ft, is built specifically for laboratories and offices. It has been fitted with specifications desired by Dr Reddy's for the purpose of undertaking work in Chemistry, Biology and Analytics.The expanded capacity will help facilitate an initial doubling of scientific staff at Chirotech while providing for further capacity additions in future. The new facility is part of the Custom Pharmaceutical Services (CPS) business unit of Dr Reddy's. It will offer these services to customers globally.
The additional capacity will help facilitate an initial doubling of scientific staff in Chirotech while providing for further capacity additions in future, the company said. It is expected to strengthen core capabilities in biocatalysis and chemocatalysis, build capacities in fast growing segments and allow development of other areas of expertise in chemistry and processing for use in the pharmaceutical industry. The new facility is part of the custom pharmaceutical services business unit of Dr Reddy's and will offer these expandedservices to its customers worldwide.
Dr. Reddy's Laboratories Ltd. founded in 1984 by Dr. K. Anji Reddy, has become India's second biggest pharmaceutical company. Reddy's manufactures and markets a wide range of pharmaceuticals in India and overseas. The company has over 190 medications, 60 active pharmaceutical ingredients for drug manufacture, diagnostic kits, critical care, and biotechnology products. Dr. Reddy's began as a supplier to Indian drug manufacturers, but it soon started exporting to other less-regulated markets that had the advantage of not having to spend time and money on a manufacturing plant that that would gain approval from a drug licensing body such as the U.S. Food and Drug Administration (FDA). By the early 1990s, the expanded scale and profitability from these unregulated markets enabled the company to begin focusing on getting approval from drug regulators for their formulations and bulk drug manufacturing plants in more-developed economies. This allowed their movement into regulated markets such as the US and Europe.
Collaboration between Dr Reddy's and Cambridge is only one of the examples of India-UK collaboration in R & D but the actual potential is quite immense and is yet to be tapped. To ensure quick progress on these collaborations the two countries have bolstered their relationship and have accommodated innovation in various sectors.The two countries see considerable potential for growth in Research, Science and Technology collaboration.They share the vision for further strengthening their partnership through new and existing initiatives and the endeavor is to widen discussion to all research funding bodies in bothcountries.It has been felt that that along with academia-business collaboration,the focus should also be on developing commercial and semi-commercial models. The India-UK science and innovation council works to promote this purpose.The main objective of creating such Council was with a view to develop further strategic science, technology and innovation bilateral relationships and agree vehicles to enhance cooperation in areas of mutual interest.
© Copyright ETI Dynamics Ltd. 2011. You can share articles and reports using the share tools where possible. Please do not cut content from the tiCorridors.com and paste into emails for distribution purposes or on to other websites.